Press release

Interim Report - 1 January - 30 June 2008

• BioInvent and ThromboGenics entered into a strategic license agreement with Roche for

• The first Phase l study with TB-403, for treatment of cancer, has been completed. TB-403

• The first patients have been enrolled in the second Phase I trial with TB-403, a multi-dose

• Two drug interaction studies with the drug TB-402, for the prevention of blood clots, are

• The Phase I programme with product candidate BI-204 for treatment of atherosclerosis

• Entered into an agreement with Bayer HealthCare for research and development of

• Net revenues for January - June 2008: SEK 211.8 million (130.3).

• Current investments together with cash and bank as of 30 June 2008: SEK 121.7 million

• Cash flow from current operations and investment activities for January - June 2008:

• Profit after tax for January - June 2008 amounted to SEK 93.8 million (40.4) and the profit after tax per share was SEK 1.68 (0.86).

BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer, atherosclerosis and ophthalmic diseases.

Comments by the CEO
Over the past eighteen months we have signed agreements for our development projects with two major companies in antibody-based drugs - Genentech and Roche, which must once again be considered as an acknowledgment of our technology and our organization. The agreement with Roche for our cancer drug TB-403 ensures the best prospects for the product candidate to progress through the upcoming clinical programme to the market. Roche has shown its strength in developing both antibody-based drugs and angiogenesis inhibitors for cancer treatment.